Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
M. Ager
Observed names:
M Ager,
Miranda Ager
Institution:
GlaxoSmithKline (United Kingdom)
Observed institution:
GlaxoSmithKline (United Kingdom)
OpenAlex ID:
A5036005993
Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia
2018
·
Dirk J. Blom
, Marina Cuchel
, et al.
·
Orphanet Journal of Rare Diseases
·
44
PDF
Psy56 Systemic Lupus Erythematosus (sle): Understanding the Burden
2010
·
M Schneider
, A Schmeding
, et al.
·
Value in Health
·
22
PDF
Pcv5 - Real-world Ldl-c Changes Experienced With Lomitapide Modelled to Potentially Increase Life-expectancy in Homozygous Familial Hypercholesterolemia (hofh)
2018
·
M. Ager
, H. Phillips
·
Value in Health
·
2
Achievement of European atherosclerosis society (EAS) targets with lomitapide, a microsomal transfer protein inhibitor in homozygous familial hypercholesterolaemia (HoFH)
2016
·
H. Phillips
, M. Ager
, et al.
·
Atherosclerosis
·
1
PSY17 Retrospective Chart Review Study of the Cost of Care of Systemtic Lupus Erythematousus (Sle) in Five European Countries
2011
·
A. Doria
, Z. Amoura
, et al.
·
Value in Health
Show more works
View as search
Works count:
5
Citation count:
69
H-index:
2
I10-index:
2
Year
Topic
Type